NIH Indirect Cost Cap Dropped: What Grant Seekers Need to Know Now

Hook: NIH Indirect Cost Cap Battle Ends in Favor of Research Institutions

In a major win for the U.S. research community, the Trump administration has officially abandoned its push to impose a 15% cap on NIH indirect cost reimbursements. By letting the Supreme Court filing deadline lapse on April 8, 2026, the government cemented a federal appeals court's earlier ruling that declared the NIH policy unlawful. For universities, academic medical centers, and research hospitals, this decision secures billions annually to cover essential overhead—averting lab closures, layoffs, and a massive funding shortfall.

Context: Averted Crisis After 14 Months of Uncertainty

For over a year, research institutions have faced existential uncertainty. The cap—first announced by NIH in February 2025 (Notice NOT-OD-25-068)—would have slashed indirect cost recovery from the typical 30–70% range down to just 15% for all new and existing grants. This move threatened to cut $4–6.5 billion annually from NIH's $47 billion budget, putting basic infrastructure, staff salaries, and scientific support services at risk.

Legal battles quickly ensued, with universities, the AAMC, and advocacy groups challenging the policy as an unlawful override of longstanding negotiated rates. Federal courts agreed, citing both HHS regulations and a 2017 congressional provision that barred NIH from altering indirect cost recovery methods. NIH’s cap was struck down by a permanent injunction in January 2026—and now, with the administration dropping its Supreme Court petition, that decision stands permanently.

Attempts to impose similar caps at NSF, DoD, and DOE were also abandoned after legal losses. Congress renewed its restriction against changes to indirects for another year, and agency efforts across science funding have been effectively halted for now.

Impact: What This Means for Researchers, Institutions, and Nonprofits

For universities, hospitals, and research institutes:

• You can continue to recover your full negotiated Facilities & Administrative (F&A) rates on NIH grants. That means tens or even hundreds of millions per year for R1 universities and large academic centers are secure—Johns Hopkins alone stood to lose over $800 million annually.
• Indirect cost recovery sustains critical infrastructure: core labs, utility bills, compliance offices, and administrative staff. These funds are not optional extras; they keep the research engine running.
• Large-scale loss of F&A would have directly reduced staff, closed labs and clinics, and forced institutions to scale back NIH-funded research. An AAMC analysis warned the cap would cut about 2,000 new NIH grants per year.

For PIs and research teams:

• Your future and renewal applications will be budgeted under your institution’s current negotiated F&A rates—study sections won’t discount indirects, and you won’t face a new layer of bureaucratic uncertainty.
• Ongoing grants are also protected; you won’t see mid-cycle rate cuts.
• Staff retention just became significantly more secure, especially for technical and administrative personnel often funded via indirects.

For community-based nonprofits and research consortia:

• If you have a federally negotiated indirect rate, you are protected. If you rely on pass-through funding from larger institutions, funding stability upstream should benefit you as well.
• Stable overhead recoveries may help anchor collaborative research or public health programs that depend on big research institutions as administrative hubs.

Action: What Should You Do Now?

1. Review your indirect cost agreements: Confirm the status of your institution’s negotiated rate with your grants office. Use this rate for all NIH proposals going forward. If your organization does not have a negotiated rate, consider initiating that process with your cognizant federal agency.

2. Audit budget development procedures: Now is the ideal time to resume business as usual—but also to review how your proposals justify and allocate indirect costs, as scrutiny and calls for accountability are likely to continue.

3. Track Congressional appropriations: The bar on changing indirect cost methods remains—but only for the upcoming year. Advocacy with professional organizations (like AAMC or COGR) is still essential to ensure continued protection.

4. Diversify funding sources: With looming threats of future policy changes (including a potential new executive order favoring low-indirect applicants and possible FY2027 NIH budget cuts), institutions should continue to explore industry, philanthropic, and private foundation support. Be aware that many private and philanthropic funders (e.g., HHMI) cap indirects significantly lower than NIH.

Outlook: What’s Next?

This policy fight may be over, but the climate for indirect cost recovery remains volatile. Advocates are pushing for greater transparency and accountability, including a possible future move toward the “FAIR” model. An August 2025 executive order may give preference to applicants with lower indirect rates, and the FY2027 federal budget process will likely revive debates over NIH spending and diversity, equity, and inclusion initiatives. Grant seekers—and especially institutional research leaders—should be ready to mobilize again if these conversations re-emerge in Congress or the executive branch.

For more updates and strategies on navigating federal grant policy changes, Granted AI makes it easier to stay ahead and maximize your funding success.